Type 2 diabetes medications

Result from ONWARDS 5 trial show weekly insulin icodec plus a dosing app offers greater reductions in glycated hemoglobin than daily basal insulin analogs for type 2 diabetes.

Novel model for risk prediction of kidney disease progression and efficacy of SGLT2 inhibition in patients with type 2 diabetes.

SGLT2 inhibitors and GLP-1 receptor agonists appear to offer the best protection against major adverse cardiovascular events in people with type 2 diabetes.

Treating people with type 2 diabetes with the triple agonist retatrutide shows promising improvements in both glycemic control and reduction in obesity.

Improved glycemic control and weight loss seen with the coadministration of cagrilintide and semaglutide in a phase 2 trial.

SURMOUNT-2 trial results show bodyweight reductions with tirzepatide that rival those seen with other approved anti-obesity medications in people with type 2 diabetes.

Finerenone modifies the risk for chronic kidney disease associated cardiovascular events in patients with type 2 diabetes and moderate-to-severe albuminuria, FIDELITY study findings indicate.

Using liraglutide in people with obesity and prediabetes is a valuable strategy for weight loss, but improvements are greater with caloric restriction alone, suggest study results.

Different antidiabetic medications commonly used in addition to metformin for type 2 diabetes have a similar effect on kidney function.

The results of ONWARDS 2 show significantly improved glycemic control with weekly insulin icodec versus daily insulin degludec, without significantly increased hypoglycemia, in people with type 2 diabetes.

Findings from a Scottish national cohort study show that the use of sulfonylureas as second-line glucose-lowering therapy is not associated with elevated cardiovascular risk or all-cause mortality.

A multifaceted, clinic-level intervention results in a marked increase in the proportion of people with type 2 diabetes and atherosclerotic cardiovascular disease receiving appropriate medications, shows the COORDINATE randomized trial.

Use of intermittently scanned continuous glucose monitoring is associated with an increased likelihood for treatment intensification in people with type 2 diabetes, a study shows.

A meta-analysis suggests that glucagon-like peptide-1 receptor agonists may help prevent new-onset heart failure in people with type 2 diabetes.

Empagliflozin, but not linagliptin, provides “clinically relevant” improvements in glycemic control versus placebo in children and adolescents with type 2 diabetes, report the DINAMO investigators.

People with type 2 diabetes who maintain low glycated haemoglobin levels have slower progression of frailty over time than those with higher levels, shows an analysis of Look AHEAD participants.

Click through to read more on this announcement

Metformin use is associated with a significant reduction in the risk for total knee or hip replacement among people with type 2 diabetes, shows research published in CMAJ.

A randomized trial reveals benefits of intermittent fasting, without an increased risk for severe hypoglycemia, in people with insulin-treated type 2 diabetes.

Allowing people to try out medications for type 2 diabetes and choose their preferred one is a viable approach in the absence of a clear clinical indication, say the TriMaster investigators.